1. Home >
  2. M&A >
  3. Divestiture >
  4. Japan >
  5. neuraxpharm Acquires Takeda Pharmaceutical Co. - Buccolam

M&A Deal Summary

neuraxpharm Acquires Takeda Pharmaceutical Co. - Buccolam

On September 14, 2020, neuraxpharm acquired life science company Takeda Pharmaceutical Co. - Buccolam from Takeda

Acquisition Highlights
  • This is neuraxpharm’s 2nd transaction in the Life Science sector.
  • This is neuraxpharm’s 1st transaction in Japan.

M&A Deal Summary
Date 2020-09-14
Target Takeda Pharmaceutical Co. - Buccolam
Sector Life Science
Buyer(s) neuraxpharm
Sellers(s) Takeda
Deal Type Divestiture

Target

Takeda Pharmaceutical Co. - Buccolam

Osaka, Japan
Takeda Pharmaceutical Co. Ltd. - Buccolam is the only buccal midazolam approved across Europe. This value-added product is indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures (PACS), the most common neurological emergency in children with an incidence of 18 to 23 cases per 100,000 per year.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

neuraxpharm

Langenfeld, Germany
Category Company
Founded 1985
Sector Life Science
Revenue 460M EUR (2019)
DESCRIPTION

neuraxpharm is a provider of generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS). neuraxpharm was formed in 1985 and is based in Langenfeld, Germany.

DEAL STATS #
Overall 2 of 4
Sector: Life Science M&A 2 of 3
Type: Divestiture M&A Deals 1 of 1
Country: Japan M&A 1 of 1
Year: 2020 M&A 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-22 Easypharm OTC

Gießhübl, Austria

Easypharm OTC GmbH is a consumer healthcare company. easypharm focuses purely on Consumer Healthcare via, among others, its two leading CNS brands, easysleep®, and easyrelax®. Easypharm OTC GmbH was established in 2008 and is based in Gießhübl, Austria.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-14 Aribamed

Dublin, Ireland

Aribamed provides and maintains important niche medicines on the Irish market for use by specialists, who find them for some patients. Aribamed partners with pharmaceutical manufacturers to commercialize niche pharmaceuticals with differential benefits for individual patients on the Irish market to support medical specialists in hospitals and specialist centers Aribamed was founded in 2007 and is based in Dublin, Ireland.

Buy -

Seller(S) 1

SELLER

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,455
Revenue 4.58T JPY (2025)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 4 of 6
Sector: Life Science M&A 2 of 3
Type: Divestiture M&A Deals 4 of 6
Country: Japan M&A 3 of 5
Year: 2020 M&A 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-26 PvP Biologics

San Diego, California, United States

PvP Biologics, Inc. is a developer of an oral enzyme for the treatment of celiac disease. PvP Biologics is based in San Diego, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-16 TachoSil

Osaka, Japan

TachoSil provides surgical patches used for bleeding control.

Sell $564M
Mergr

Solution for

Product

Company

Legal